Clinical Trials Logo

Filter by:
NCT ID: NCT01231854 Terminated - Atopic Dermatitis Clinical Trials

Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.

TocyDD
Start date: November 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the comparative efficacy, safety and efficiency of ciclosporin microemulsion and alitretinoin in adults with severe atopic hand dermatitis.

NCT ID: NCT01231555 Terminated - Clinical trials for Infection, Human Immunodeficiency Virus

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)

SIGNET
Start date: November 18, 2010
Phase: Phase 2
Study type: Interventional

This 96 week, Phase 2b study in 150 HIV-1 infected antiretroviral (ART) naive adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of open-label efavirenz (EFV) 600 mg once daily. The background ART for all 3 arms will be chosen by the Investigators and will be either abacavir/lamivudine [ABC/3TC] or tenofovir/emtricitabine [TDF/FTC] fixed dose combination (FDC) tablets. Antiviral activity, safety, PK, and development of viral resistance will be evaluated.

NCT ID: NCT01231347 Terminated - Cancer Clinical Trials

QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

GAMMA
Start date: April 2011
Phase: Phase 3
Study type: Interventional

AMG 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF-1R). Signaling through IGF-1R plays an important role in the regulation of cell growth and survival. Gemcitabine is administered on days 1, 8 and 15 of a 28 day cycle, AMG 479 or placebo is administered on days 1 and 15 of the 28 day cycle, both are administered intravenously. The primary purpose of the study is to determine if AMG 479 and gemcitabine improves overall survival as compared to placebo and gemcitabine.

NCT ID: NCT01230827 Terminated - Clinical trials for Juvenile Idiopathic Arthritis

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

Start date: December 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in patients who have active juvenile idiopathic arthritis (JIA) and at least 5 joints with active arthritis that have poor response to methotrexate.

NCT ID: NCT01226745 Terminated - Multiple Sclerosis Clinical Trials

A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis

DreaMS
Start date: October 2010
Phase: Phase 2
Study type: Interventional

The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in patients with relapsing-remitting multiple sclerosis (RRMS) in patients who have completed an initial 26-week study (ONO-4641POU006).

NCT ID: NCT01226238 Terminated - Clinical trials for Major Depressive Disorder

Online Self-help for Depressed Patients Awaiting Psychotherapy

Start date: October 2010
Phase: N/A
Study type: Interventional

Patients with major depression who are on a waiting list for psychotherapy usually suffer from considerable symptoms. Online self-help is one potential way to alleviate this suffering. The investigators want to study if patients awaiting psychotherapy benefit from online-self help. The investigators therefore randomly assign patients to either online self-help or no intervention and assess their depressive symptoms on a regular basis. The investigators hypothesize that online self-help will be superior to no intervention in alleviating depressive symptoms in depressed patients awaiting psychotherapy.

NCT ID: NCT01222078 Terminated - Clinical trials for Diabetes Mellitus, Type 1

Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus

Start date: November 22, 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study to assess the safety and tolerability of re-dosing at 6 months with otelixizumab (given as an 8-day series of intravenous infusions) in adult subjects with newly diagnosed type 1 diabetes mellitus

NCT ID: NCT01220427 Terminated - Prostate Cancer Clinical Trials

Micro-RNA Expression Profiles in High Risk Prostate Cancer

Start date: June 2007
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether specific Micro-RNA expression profiles are related to Prostate cancer outcome.

NCT ID: NCT01220128 Terminated - Neoplasms, Breast Clinical Trials

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

INDUCT
Start date: April 11, 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer. The treatment will be given before surgery in combination with standard therapy.

NCT ID: NCT01216657 Terminated - Clinical trials for Chemo-refractory Melanoma

Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

Start date: March 2009
Phase: Phase 2
Study type: Interventional

Sunitinib is a novel small molecule receptor tyrosine kinase inhibitor with direct antitumor effects as well as antiangiogenetic activity. Preclinical and clinical data for Sunitinib and data about angiogenesis and growth regulation in melanoma suggest the activity of Sunitinib in melanoma. This study will investigate the efficacy, safety and tolerability of Sunitinib as palliative treatment in chemo-refractory metastatic melanoma.